Ozempic Lawsuit | Ozempic and Wegovy Claims
- Last Updated: July 9th, 2024
Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
Legally Reviewed
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
Fact-Checked
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Key takeaways:
- Ozempic and Wegovy, used for diabetes management and weight loss, are under investigation for causing stomach paralysis.
- An Ozempic Lawsuit and other legal actions are being explored for patients who suffered stomach paralysis after using these drugs.
- While no FDA warnings exist for Ozempic and Wegovy, there are warnings for their compounded versions.
Ozempic Lawsuit Overview
On this page we’ll discuss the potential of an Ozempic Lawsuit, what drugs like Ozempic and Wegovy are designed to do, side effects associated with Ozempic, who may qualify for an Ozempic Lawsuit, and much more.
Intro to the Ozempic Lawsuit & Stomach Paralysis Claims
Ozempic is an FDA approved drug originally used to improve blood sugar in adults with type 2 diabetes, but has been popularize for weight loss.
Wegovy is an FDA approved drug used for chronic weight management in adults with obesity.
These drugs, or compounded versions of these drugs, may be linked to severe gastroparesis (stomach paralysis), gallbladder disease, cyclic vomiting syndrome, and other serious medical conditions.
Stomach paralysis is a condition affecting nerves and muscles in the stomach, interfering with the process that moves food through the stomach and into the small intestine.
Symptoms and side effects of stomach paralysis can be painful, uncomfortable, and may lead to long-term health problems.
Gallbladder disease involves conditions like gallstones and inflammation (cholecystitis), which can cause discomfort and may require gallbladder removal.
Legal action is being investigated for these symptoms and injuries.
If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.
Contact TruLaw for a free consultation.
You can also use the chatbot on this page for an instant case evaluation.
Table of Contents
Lawsuit Updates
-
July 2024 Updates:
A recent study published in JAMA Ophthalmology indicates that patients using Ozempic and Wegovy may have a higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition leading to sudden vision loss.
Key findings include:
- Diabetic patients on Semaglutide medications are over four times more likely to develop NAION.
- Overweight or obese individuals using these drugs face a sevenfold increase in risk.
- Approximately 100 cases were identified annually over six years, with the highest risk observed within the first year of medication use.
Novo Nordisk, the manufacturer of Ozempic and Wegovy, acknowledges the study but maintains that the data does not establish causation.
Despite the potential risk, NAION remains relatively uncommon compared to the benefits provided by these medications.
The U.S. Food and Drug Administration (FDA) lists vision changes among the possible side effects of semaglutide.
Novo Nordisk is conducting ongoing trials to explore the link between semaglutide use and diabetic retinopathy, with results expected by 2027.
Experts recommend that patients taking semaglutide or considering treatment discuss the risks and benefits with their doctors, particularly those with other optic nerve issues such as glaucoma or preexisting visual loss.
If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.
Contact TruLaw for a free consultation.
You can also use the chatbot on this page for an instant case evaluation.
-
June 2024 Updates:
June 26, 2024
A recent study from the University of Copenhagen raises new concerns about GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, highlighting potential bone density loss.
Published in JAMA Network Open, the study found that using these medications without combining them with exercise can lead to a decrease in bone mineral density (BMD) in critical areas like the hips and spine.
Ozempic, initially approved for Type 2 diabetes in 2017, has gained popularity as a weight loss drug. Its active ingredient, semaglutide, is also present in Wegovy, a higher-dose version specifically for weight loss.
Despite aggressive marketing promoting these drugs as safe and effective, GLP-1 medications have been linked to severe health risks, including gastroparesis—a condition where the stomach is paralyzed, leading to long-term gastrointestinal issues.
Thousands of lawsuits have been filed against the manufacturers for allegedly failing to warn about these risks, prioritizing profits over consumer safety.
The latest study by Dr. Simon Birk Jensen and colleagues involved a randomized clinical trial with 195 participants.
The findings revealed that participants who combined GLP-1 treatment with exercise achieved the most significant weight loss while maintaining bone health.
Those who used Victoza alone experienced a decrease in BMD.
The study showed the necessity of exercise to mitigate the decrease in bone mineral density associated with GLP-1 medications.
If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.
Contact TruLaw for a free consultation.
You can also use the chatbot on this page for an instant case evaluation.
June 25, 2024Recent research highlights a significant concern for users of glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly prescribed for diabetes management.
A study published in Gastroenterology on March 27, 2024, indicates an increased risk of aspiration pneumonia associated with GLP-1RA use during endoscopic procedures involving propofol sedation targeting the upper gastrointestinal tract.
The retrospective cohort study analyzed health records from 80 healthcare organizations, involving adults aged 21 to 70 who underwent upper and lower endoscopies between 2018 and 2020.
Results show that GLP-1RA users, defined as individuals with a history of use exceeding six months and with at least two refills within six months prior to the procedure, experienced a higher incidence rate of aspiration pneumonia (0.83%) compared to nonusers (0.63%), corresponding to a hazard ratio of 1.33.
This risk was notably higher in procedures involving propofol sedation, specifically upper GI endoscopies, with no significant risk noted in lower GI procedures.
Dr. Ali Rezaie, Medical Director of Gastroenterology Motility at Cedars-Sinai Medical Center, emphasized the need for context, noting that while the relative risk increases by 33%, the absolute risk remains low at 0.2%.
Conversely, the American Gastroenterological Association has not found evidence to support this precaution in their latest clinical update.
Despite this, some medical centers, including Cedars-Sinai, have begun advising patients to discontinue GLP-1RA use one week prior to elective procedures.
Further guidance is expected as new recommendations are being developed, reflecting a cautious approach towards managing the increased risk of aspiration in GLP-1RA users.
If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.
You can also use the chatbot on this page for an instant case evaluation.
June 21, 2024
A mass tort lawsuit is currently underway in a federal court in Philadelphia, addressing serious concerns regarding the safety and regulatory oversight of widely used weight-loss medications including Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro.
These drugs, primarily known as GLP-1 agonists, were initially approved for managing Type 2 diabetes but have gained popularity for weight loss purposes.
Recent data reveals a significant surge in their usage, with over 15 million Americans using these medications as of last month, marking a substantial increase in prescriptions by 40 times since 2018.
The core of the lawsuit alleges that Novo Nordisk and Eli Lilly, the manufacturers of these drugs, failed to provide sufficient warnings about potential severe gastrointestinal side effects.
Reported adverse effects include gastroparesis, intestinal obstructions, and pancreatitis, concerns that have been substantiated by recent studies and warnings from the Food and Drug Administration (FDA).
Legal experts indicate that this case not only scrutinizes the drug manufacturers but also casts doubt on the FDA’s approval and monitoring processes.
The ramifications of this lawsuit could extend beyond the courtroom, potentially leading to stricter regulatory measures for GLP-1 agonists and impacting their future market availability and consumer trust.
Amidst growing endorsements from celebrities and increasing awareness of their health benefits, these weight-loss drugs have experienced a surge in demand.
However, the ongoing lawsuit and the negative publicity surrounding it could temper future demand.
he outcome of this litigation holds significant implications for drug safety perceptions and the broader regulatory landscape of pharmaceuticals.
If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.
You can also use the chatbot on this page for an instant case evaluation.
June 7, 2024
The Ozempic lawsuit is growing as more consumers become aware of GLP-1 side effects.
The U.S. Judicial Panel on Multidistrict Litigation (JPML) has recently transferred the combined litigation concerning Ozempic, Wegovy, and Mounjaro to U.S. District Judge Karen Marston in the Eastern District of Pennsylvania, following the unexpected passing of U.S. District Judge Gene E.K. Pratter.
Under the oversight of Judge Marston, the case now encompasses over 10,000 personal injury claims.
This litigation centers on serious claims against pharmaceutical giants Novo Nordisk and Eli Lilly and Co., alleging that they failed to adequately warn users about potential severe digestive side effects associated with these GLP-1 class drugs, which are commonly prescribed for diabetes management and weight loss.
Plaintiffs have linked these medications to severe health issues such as gastroparesis, intense vomiting, and bowel obstruction.
Significant legal proceedings include the completion of the plaintiff’s fact sheet, which will outline each claimant’s injuries, medical conditions, and specific drug usage.
While defense attorneys see this phase as a chance to potentially reduce the case’s breadth by dismissing claims related to counterfeit products or those without proper medical diagnoses, plaintiffs’ lawyers are contesting any premature dismissals.
They advocate for further discovery and the initiation of bellwether trials to comprehensively address and resolve the allegations.
Given the substantial public attention and the extensive use of these medications—reported to be used by one in eight U.S. adults—Judge Marston is expected to move forward with these proceedings.
If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.
You can also use the chatbot on this page for an instant case evaluation.
-
May 2024 Updates:
May 29, 2024:
The Ozempic lawsuit is growing as more consumers become aware of GLP-1 side effects.
The Ozempic lawsuit continues to gain attention as increasing numbers of consumers report severe side effects from GLP-1 receptor agonists, including Ozempic and Wegovy, which doctors frequently prescribe for managing obesity and diabetes.
Concerns are escalating about the risk of gastroparesis, a condition commonly known as stomach paralysis, which is often associated with these medications.
Gastroparesis slows down gastric emptying, leading to significant discomfort and complicating the management of metabolic diseases.
Recent studies highlight the risk of developing gastroparesis from GLP-1 medication use:
- Research unveiled at Digestive Week 2024 indicates a rise in gastroparesis occurrences in patients using GLP-1 drugs compared to those not taking these medications.
- A University of Kansas study, which reviewed health records of nearly 150,000 patients, found a 66% increased diagnosis rate of gastroparesis among individuals treated with GLP-1s.
- Further research by University Hospitals in Cleveland, examining over 336,000 individuals, discovered that the likelihood of developing gastroparesis increases after six months of GLP-1 therapy.
Although the overall risk is less than 1%, the data consistently show a significant relative increase.
As the popularity of Ozempic and Wegovy persists in diabetes and obesity management, ongoing investigations into their side effects, such as gastroparesis, are essential for patient safety.
Our Ozempic lawyers are actively investigating cases involving stomach paralysis and other severe side effects from these medications.
If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.
Contact TruLaw for a free consultation.
You can also use the chatbot on this page for an instant case evaluation.
May 23, 2024Awareness surrounding Ozempic and other GLP-1 drugs continues to grow.
The Ozempic multidistrict litigation is facing an unexpected complication due to the abrupt and tragic passing of U.S. District Judge Gene E.K. Pratter on May 17, 2024.
Judge Pratter, who was presiding over the Ozempic MDL in the Eastern District of Pennsylvania, passed away at the age of 75.
Judge Pratter’s death may have an impact on the ongoing Ozempic Lawsuits, which allege severe gastrointestinal side effects from glucagon-like peptide-1 (GLP-1) receptor agonists used in diabetes and weight loss treatments.
Some estimates indicate that nearly 2% of the U.S. population has been prescribed one of the GLP-1 medications, either for diabetes treatment or weight loss, it was widely expected that the litigation would become a major mass tort in the coming months.
These lawsuits claim that the drug manufacturers, including Novo Nordisk and Eli Lilly, failed to adequately warn users about the risks of medications such as Ozempic, Wegovy, and Mounjaro.
At the time of her passing, Judge Pratter was managing the initial stages of the MDL, which had been formed in February 2024, the MDL included 87 active lawsuits as of May 1, with expectations that the number could grow to several thousand due to the widespread use of these medications.
The reassignment of these cases to a new judge is now necessary, a process that will involve the review of existing records and a thorough understanding of the scientific and medical evidence, which could delay the proceedings.
A planned “Ozempic Science Day” on June 14, intended to clarify the scientific claims of the litigation, is now uncertain.
As the judicial system manages this transition, the continuity of the Ozempic MDL will be a priority.
If you or a loved one has suffered injuries from Ozempic or other GLP-1 drugs, you may be eligible to file a claim.
Contact us for a free consultation, or use the chatbot on this page to find out if you qualify for the Weight Loss Drugs Lawsuit.
May 21, 2024
Awareness surrounding Ozempic and other GLP-1 drugs continues to grow.
Growing concerns have surfaced regarding the serious side effects of Ozempic, a popular weight loss medication.
Medical professionals and patients report a range of adverse reactions linked to this drug and other GLP-1 medications.
A detailed examination reveals more than 9 million prescriptions of Ozempic were issued in the fourth quarter of 2022 alone.
Despite the high prescription rates, the number of users could be substantially higher, as many individuals obtain the drug without proper medical oversight due to insurance constraints.
Our Ozempic lawyers are closely monitoring the situation, as patients report severe side effects such as gastroparesis (stomach paralysis), gallbladder disease, cyclic vomiting syndrome, and more.
If you or a loved one has suffered injuries from Ozempic or other GLP-1 drugs, you may be eligible to file a claim.
Contact us for a free consultation, or use the chatbot on this page to find out if you qualify for the Weight Loss Drugs Lawsuit.
May 9, 2024
The Ozempic Lawsuit is progressing through the early stages in multidistrict litigation.
On May 9, 2024, U.S. District Judge Gene Pratter of Philadelphia officially appointed four attorneys as lead counsel in the multidistrict litigation (MDL) against diet drug manufacturers Novo Nordisk and Eli Lilly.
The legal proceedings have garnered attention not only for the nature of the claims but also for the nature of the claims but also for the innovative approach to selecting lead counsel, which could set a precedent for future large-scale litigations.
Judge Pratter’s method involves a combination of self-selection by a state of proposal lead counsels and confirmation through consensus among other plaintiffs’ lawyers.
The process led by Judge Pratter aims to streamline the complex management of thousands of cases in the Ozempic MDL.
As the Ozempic cases progress, the spotlight remains on the safety profile of these drugs.
Plaintiffs allege that side effects were not fully disclosed, impacting patient health when used as prescribed for diabetes management and weight loss.
Novo Nordisk has defended the safety of Ozempic by stating that all potential side effects are disclosed as per regulatory requirements.
If you or a loved one have suffered from stomach paralysis or other serious side effects from Ozempic, Wegovy, or other GLP-1 drugs, you may be eligible to file a claim.
Contact us for a free consultation, or use the chatbot on this page to find out if you qualify for an Ozempic Lawsuit.
-
March 2024 Updates:
March 21, 2024
The litigation surrounding Ozempic and other weight loss drugs is currently in the preliminary phase, and the number of lawsuits is expected to grow as the court sets the guidelines for filing cases.
A growing number of individuals are initiating legal actions against pharmaceutical leaders Eli Lilly and Novo Nordisk.
These firms manufacture a category of drugs known as GLP-1 agonists, which encompasses popular diabetes and weight loss medications like Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro.
The plaintiffs allege that they experienced severe digestive complications, including the necessity for gallbladder removal and the development of gastroparesis, due to using these drugs.
U.S. District Judge Gene E. K. Pratter in Philadelphia is overseeing the consolidation of these legal actions because of the similar complaints regarding the adverse effects of these medications.
A significant portion of these legal challenges is directed at Novo Nordisk, the producer of Ozempic and Wegovy, with the potential for the total number of cases to reach into the thousands as more affected individuals step forward.
Novo Nordisk asserts the safety and effectiveness of its GLP-1 drugs, pointing to their 13-year presence on the market and thorough safety assessments conducted in partnership with the U.S. Food and Drug Administration (FDA).
This legal battle underscores the enormous popularity of GLP-1 drugs in the United States, utilized for both diabetes treatment and weight management.
With projections indicating 30 million users by 2030 and revenues exceeding $1 billion, the implications are significant for both the pharmaceutical sector and those claiming injuries from these drugs.
If you or someone you know has suffered from gastroparesis or other health issues after using Ozempic or similar GLP-1 medications, you might qualify for a weight loss drug lawsuit.
Reach out to TruLaw for a free, no obligation consultation.
For an immediate case evaluation, utilize the chatbot available on this webpage.
-
February 2024 Updates:
February 19, 2024
The Ozempic Lawsuit is developing, with legal actions focusing on claims related to severe gastrointestinal injuries attributed to the use of Ozempic and similar GLP-1 receptor agonist drugs.
As of early 2024, a federal panel has consolidated at least 55 lawsuits into a multidistrict litigation (MDL) in the Eastern District of Pennsylvania.
Ozempic Lawsuits allege that manufacturers Novo Nordisk and Eli Lilly, which also produces GLP-1 drugs, failed to adequately warn users about the potential for severe side effects such as gastroparesis (a condition causing delayed stomach emptying), intestinal obstruction, and other gastrointestinal injuries associated with these medications.
The consolidation into an MDL is aimed at streamlining the proceedings and ensuring consistent rulings across all cases.
The plaintiffs argue that despite the inclusion of warnings on the drug labels, the companies downplayed the severity of gastrointestinal issues.
The MDL includes claims related to a variety of drugs, including Novo Nordisk’s Ozempic, Wegovy, Rybelsus, and Eli Lilly’s Trulicity and Mounjaro.
Ozempic Lawyers anticipate that the number of lawsuits could grow significantly as part of the MDL.
A Louisiana federal judge largely rejected Novo Nordisk’s bid to dismiss the lawsuit, allowing the case to move forward, particularly on claims related to failure to warn about the risk of gastroparesis.
Ozempic Lawsuits and legal actions regarding other GLP-1 drugs highlight the importance of patients being fully informed about the potential side effects of weight loss medications, including those that could have severe implications for their health.
The consolidation of Ozempic Lawsuits into multidistrict litigation underscores the growing concern and legal scrutiny over the alleged severe side effects of Ozempic, Mounjaro, and other similar drugs.
If you or a loved one have suffered injuries after taking Ozempic or other similar drugs, you may be eligible to file an Ozempic Lawsuit.
Contact us for more information or use the chatbot on this page to find out if you qualify for the Ozempic Lawsuit instantly.
February 18, 2024
Lawsuits against the makers of Ozempic and other similar drugs are growing, and the highly popularized medication is continuing to make news headlines for the wrong reasons.
A 60-year-old Illinois resident claims that her use of Ozempic resulted in a blocked bowel and violent vomiting, leading to a torn esophagus which required a week-long hospitalization.
Ozempic, a weekly injection that helps lower blood sugar by helping the pancreas make more insulin, is also used to help mitigate weight gain and can help with weight loss.
This case signals a significant moment in the growing controversy over the blockbuster weight loss drug’s alleged severe side effects.
The injured Illinoisan’s case joins nearly 60 others alleging that Ozempic and Wegovy, another Novo Nordisk product, caused stomach paralysis among other debilitating conditions and side effects.
With a centralization of lawsuits in a Pennsylvania federal court, pharmaceutical companies face a troubling legal challenge.
February 5, 2024
As of February 5, 2024, the legal proceedings concerning Ozempic continue, and attorneys are still open to taking on additional cases.
The latest update from the Judicial Panel on Multidistrict Litigation (JPML) indicates that there are currently seven Ozempic-related lawsuits grouped in the recently established Multidistrict Litigation (MDL).
In the U.S., MDLs are specialized judicial procedures used to efficiently manage multiple civil lawsuits that share common factors, such as similar legal questions, facts, or defendants.
This approach is particularly useful when various parties file lawsuits concerning shared issues, like the health concerns associated with Ozempic and other drugs.
These related lawsuits are combined into one federal district court for the pretrial phase.
The primary objective of an MDL is to streamline legal proceedings.
The Ozempic Lawsuit is still ongoing.
Ozempic and Wegovy Lawsuit Investigation
New reports have indicated that a number of patients who used Ozempic and Wegovy, or compounded versions of these drugs, for weight loss have experienced serious side effects.
Stomach paralysis, a condition that affects nerves and muscles in the stomach, has been reported in multiple users of semaglutide products, specifically Ozempic and Wegovy.
Legal action is being investigated for users of Ozempic and Wegovy for these serious side effects.
If you or a loved one used Wegovy, Ozempic, or compounded versions of the drug for weight loss and subsequently developed gastroparesis, you may be eligible to file a legal claim.
Contact TruLaw for a free consultation.
You can also use the chatbot on this page for an instant case evaluation.
Our law firm is committed to helping people injured at no fault of their own seek compensation for what they’ve experienced.
Visit this page for further updates as our attorneys investigate this potential litigation.
FDA Warnings on Ozempic and Wegovy
The FDA has not yet produced warnings on the use of brand-name Ozempic and Wegovy for serious side effects, but the agency has released a warning on the use of compounded versions of the drug.
The FDA has received reports of adverse events related to compounded semaglutide products, claiming compounding pharmacies may be using salt forms of semaglutide, which are different active ingredients from those used in the FDA approved versions of Ozempic.
In addition to the FDA’s safety information page on Ozempic for weight loss, the FDA wrote to the National Association of Boards of Pharmacy about the agency’s concerns regarding the use of semaglutide salts in compounded versions of the drug.
What is the Controversy with Ozempic?
Ozempic is intended to be prescribed to diabetes patients.
Patients are required to meet medical criteria in order to obtain a valid Ozempic prescription.
Wellness clinics, compounding pharmacies, medical spas, and more have been prescribing Ozempic and compounded versions of the weight loss drug to people who do not meet criteria for prescriptions, potentially putting them at risk for serious side effects.
Novo Nordisk has even filed lawsuits against medical spas, wellness clinics, and weight loss clinics for selling illegally compounded versions.
Accusations in the lawsuit include false advertising, unfair competition, and trademark infringement.
There has been considerable media attention on Ozempic’s ability to help people shed weight in short amounts of time.
The New Yorker Magazine shed light on Ozempic’s rise in popularity among celebrities and influencers, and highlighted the drug’s potential to revolutionize how obesity and diabetes are treated.
What is Ozempic?
Ozempic is a popular diabetes drug that has been touted as a “miracle medication” used to maintain weight loss and control diets.
Ozempic (generic name: semaglutide) belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists.
Initially approved by the U.S. Food and Drug Administration (FDA) in 2017, Ozempic was primarily designed for the treatment of type 2 diabetes.
Injected weekly, its main purpose is to improve blood sugar control in adults with type 2 diabetes, helping them manage their glucose levels and reduce the risk of diabetes-related complications.
GLP-1 receptor agonists, like Ozempic, work by mimicking the action of GLP-1 hormones, which naturally occur in the body and regulate insulin release in response to food intake.
By activating the GLP-1 receptors, Ozempic promotes insulin production, suppresses glucagon secretion (a hormone that raises blood sugar levels), slows down gastric emptying, and reduces appetite.
These actions contribute to better glycemic control in individuals with type 2 diabetes.
Ozempic and Weight Loss
Beyond its intended use for diabetes management, Ozempic has garnered attention for its potential in aiding weight loss.
Ozempic has been widely popularized by celebrities, influencers and social media trends, with Variety Magazine dubbing the drug:
“The worst kept secret in Hollywood.”
Produced by Danish pharmaceutical company Novo Nordisk, Ozempic
During clinical trials, some patients treated with Ozempic experienced significant weight loss compared to those receiving a placebo or other diabetes medications.
The exact mechanisms through which Ozempic induces weight loss are not fully understood, but it is believed to be a combination of reduced appetite, delayed gastric emptying, and potential effects on the brain’s reward system, leading to lower food intake and increased feelings of satiety.
Ozempic Side Effects
Ozempic has been linked to a number of side effects in patients.
These side effects include, but are not limited to:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Loss of appetite
- Headache
- Fatigue
- Dizziness
- Hypoglycemia (low blood sugar) when used in combination with other diabetes medications
- Injection site reactions (redness, swelling, or itching at the injection site)
- Pancreatitis (inflammation of the pancreas)
- Gallbladder problems (including gallstones)
- Kidney problems
- Thyroid tumors in animal studies (the relevance to humans is uncertain)
- Allergic reactions (rare but possible, may include rash, itching, swelling, severe dizziness, or trouble breathing)
- Gastroparesis (delayed emptying of the stomach)
Ozempic Stomach Paralysis (Gastroparesis)
One significant concern is the risk of gastroparesis, a condition characterized by delayed emptying of the stomach.
Gastroparesis occurs because Ozempic, like other GLP-1 receptor agonists, slows down the rate at which the stomach empties its contents.
While this can be beneficial for diabetes management and weight loss, it can also lead to complications in some individuals.
Symptoms of gastroparesis may include:
- Nausea
- Vomiting
- Bloating
- Feelings of fullness after only eating small amounts of food
- Persistent stomach pain
- Pain in the upper abdomen
- Heartburn
In severe cases, gastroparesis can lead to malnutrition and other digestive issues.
It is crucial for individuals prescribed Ozempic to be aware of these potential side effects and report any symptoms of gastroparesis or other adverse reactions to their healthcare provider promptly.
Patients should work closely with their healthcare team to monitor their response to the medication and adjust the dosage if necessary.
Ozempic and Gallbladder Disease
Scientific evidence has linked Ozempic usage and gallbladder disease, particularly gallstones.
An initial meta-analysis indicated an elevated risk of gallbladder disease with Ozempic use.
A 2022 Research Letter, based on FDA data, provided conclusive evidence showing that Ozempic users faced a significantly increased risk of both gallstones and acute gallbladder disease.
The risk was found to be higher at higher doses, for prolonged periods, and when Ozempic was used for weight loss.
Gallbladder disease encompasses various conditions affecting the gallbladder, including gallstones (cholelithiasis), inflammation (cholecystitis), and cancer.
Cholecystitis, caused by blockage of the gallbladder’s exit tube, is a serious condition requiring immediate treatment to prevent potentially fatal complications, and the most common treatment is gallbladder removal.
Gallstones are solid deposits that form inside the gallbladder and can vary in size, categorized as cholesterol stones (more common) or pigment stones, formed from bilirubin, a byproduct of liver red blood cell breakdown.
Symptoms of gallbladder disease include:
- Abdominal pain, particularly in the upper right or center of the abdomen
- Pain that may radiate to the back or right shoulder
- Nausea and vomiting
- Bloating and gas
- Indigestion and heartburn
- Belching
- Diarrhea or light-colored stools
- Fever and chills in case of infection
- Jaundice (yellowing of the skin and eyes) in severe cases
Before April 2022, the Ozempic warning label did not include gallbladder disease as a potential side effect.
Ozempic Use and Surgery
Anesthesiologists have raised concerns about the hazards of stomach paralysis in patients taking GLP-1 agonist medications like Ozempic before surgery, as there’s little information about the risks associated with stomach slowdown on these drugs.
Stomach contents suctioned from a patient on a GLP-1 agonist showed the stomach was full despite following pre-surgery fasting instructions, leading to a risk of aspiration into the lungs, which can have severe consequences.
The American Society of Anesthesiologists recommends patients stop taking these medications one week before surgery, but the appropriate duration of fasting or discontinuation is not yet fully understood due to limited scientific evidence.
What is Wegovy?
Wegovy is a prescription medication designed to combat obesity and promote weight loss.
Approved by the U.S. Food and Drug Administration (FDA), Wegovy is a higher-dose formulation of semaglutide, which was initially used for managing type 2 diabetes under the brand name Ozempic.
Recognizing its potential in aiding weight loss, researchers developed Wegovy as a dedicated treatment for obesity.
The higher-dose formulation of Wegovy for weight loss surpasses the doses used for diabetes management, harnessing the potential for even greater weight reduction.
In studies, patients treated with Wegovy achieved significant weight loss compared to those receiving a placebo, making it a promising option for individuals struggling with obesity.
Potential for Serious Side Effects: Gastroparesis, Gallbladder Disease, and More
Like Ozempic, Wegovy and its compounded versions, may potentially slow down gastric emptying, leading to gastroparesis.
The medication may also be linked to gallbladder disease.
Patients prescribed Wegovy should be vigilant in monitoring their response to the medication and report any signs of stomach paralysis or other adverse effects to their healthcare provider promptly.
As with any medication, it is crucial for individuals to have open communication with their healthcare team to address any concerns and ensure their well-being throughout the weight loss journey.
What are Compounded Drugs?
Ozempic and Wegovy are both on the FDA drug shortage list.
FDA approved semaglutide medicines
Drug makers have produced compounded versions of Ozempic and Wegovy to combat this shortage.
Compounded versions of drugs are often prescribed when a patient cannot take commercially available medications due to specific allergies, intolerances, or dosage requirements.
In regard to Ozempic and Wegovy, compounding pharmacies have produced alternatives due to the drug shortage.
Compounded drugs, often hailed as a solution during severe drug shortages, come with a slew of inherent dangers that cannot be ignored.
Why are Compounded Drugs Made?
When legitimate pharmaceuticals are scarce due to manufacturing issues, supply chain disruptions, or discontinuation, compounding pharmacies step in to create custom-made medications.
The availability of compounded drugs might seem like a saving grace, but patients should proceed with caution.
Unlike commercially manufactured medications, compounded drugs often lack rigorous testing and quality control measures.
As a result, patients may receive medications of varying potency, purity, and effectiveness, leading to unpredictable health outcomes.
Do You Qualify for the Ozempic Lawsuit?
The Ozempic Lawsuit and Wegovy Lawsuit are potential litigations.
Our attorneys are investigating the potential for litigation on behalf of patients who took these drugs and subsequently developed stomach paralysis and other serious injuries.
If you or a loved one used Ozempic or Wegovy for weight loss and subsequently developed gastroparesis (stomach paralysis) or other related stomach problems, you may be eligible to file an Ozempic Lawsuit claim.
Contact TruLaw Law for a free consultation.
You can also use the chatbot on this page for an instant case evaluation.
Our Ozempic Lawyers will help you throughout the legal process, completing necessary steps like gathering evidence and assessing damages.
If you are experiencing stomach paralysis symptoms, contact your doctor as soon as possible.
Mitigation is another crucial part in a successful legal claim.
Gathering Evidence for the Ozempic Lawsuit
Evidence is important in product liability lawsuits, especially for a drug as popular and scrutinized as Ozempic.
Evidence in a potential Ozempic Lawsuit claim may include:
- Medical records
- Doctor’s notes
- Prescription records
- Receipts of purchase
- Witness testimony
- Photos and videos
- Personal testimony
- Any other evidence detailing your use of Ozempic and/or Wegovy and subsequent health problems
Your attorney will help you gather relevant evidence, but you can begin this step on your own to best prepare yourself for legal action.
Assessing Damages in the Ozempic Lawsuit
Damages refer to the total amount of losses, economic and non-economic, related to an incident or the use of a dangerous drug.
Potential damages in an Ozempic Lawsuit may include:
- Medical bills
- Future medical expenses
- Lost wages or earning ability
- Pain and suffering
- Emotional damages
- Lost quality of life
- Permanent disability
- Other compensatory and punitive damages
Your Ozempic Lawyer will help you assess and calculate total damages to be included in your legal claim.
Mitigating Injuries for an Ozempic Lawsuit
Mitigation is another crucial part of a successful legal claim.
Mitigating injuries refers to taking action to lessen the impact of Ozempic on your body and life.
Discuss halting use of the drug with a doctor, and explain the symptoms you are experiencing for documentary purposes.
It is also recommended to pursue treatment that your medical professional recommends.
It’s essential that you show proof of attempts to improve your condition.
TruLaw: Investigating the Ozempic Lawsuit
As mentioned, our legal team is investigating the potential safety concerns of Ozempic and Wegovy and strategizing potential legal action against manufacturers for putting consumer health at risk.
If you or a loved one used Ozempic and/or Wegovy, or compounded versions of the drugs, and subsequently developed gastroparesis (stomach paralysis) or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.
Contact TruLaw Law for a free consultation.
You can also use the chatbot on this page for an instant case evaluation.
Frequently Asked Questions
-
Is There an Ozempic Lawsuit?
The Ozempic Lawsuit is a potential litigation.
Ozempic and other similar semaglutide drugs may be linked to gastroparesis (stomach paralysis), gallbladder disease, cyclic vomiting syndrome, and other serious conditions.
The reasons for filing an Ozempic lawsuit may be based on the following key points:
- Consumers were allegedly not sufficiently warned about certain side effects and potential for injury.
- Users of Ozempic, who were later diagnosed with related stomach and gallbladder injuries may be eligible to file a claim.
- Insufficient warning labels on Ozempic and other semaglutide medications (like Wegovy) are claimed to put users at unnecessary risk for certain injuries.
Insufficient Warning About Potential Side Effects
Ozempic lawsuit claims may center around allegations that consumers who took the drug were not sufficiently warned about certain side effects.
These side effects and medical conditions include stomach paralysis, gallbladder disease, cyclic vomiting syndrome, and other stomach problems.
Eligibility to File a Lawsuit
Users of Ozempic, Wegovy, or other semaglutide medications who were later diagnosed with stomach and gallbladder injuries may be eligible to file a claim.
Dangerous drug lawsuits typically aim to pursue compensation for medical expenses, pain and suffering, and other damages.
Insufficient Warning Labels
Many dangerous drug lawsuits claim that the warning labels on medications are insufficient, putting users at unnecessary risk.
Ozempic lawsuits could be potentially filed by people who suffered injuries such as gallbladder disease, stomach paralysis, or cyclic vomiting syndrome.
To conclude, the reasons for filing an Ozempic lawsuit are primarily based on allegations of insufficient warning about potential side effects, the eligibility of patients with related health issues to file a lawsuit, and claims of insufficient warning labels on the medication.
The outcome of these lawsuits could have significant implications for the manufacturer and potentially for the wider pharmaceutical industry.
-
Is There a Lawsuit Against Ozempic and Wegovy?
The potential lawsuits against Ozempic and Wegovy for causing Gallbladder Disease and Stomach Paralysis may be based on the following key points:
- Some patients using Ozempic and Wegovy have reported severe gastroparesis (stomach paralysis) gallbladder disease, and cyclic vomiting syndrome.
- Lawsuits claim that consumers were not sufficiently warned about potential side effects, including damage to the gallbladder.
- Users of Ozempic, Wegovy, or other semaglutide medications who were later diagnosed with related gallbladder or bile duct issues may be able to file a lawsuit.
- The Ozempic lawsuits claim that the semaglutide injections can cause acute gallbladder disease.
Reports of Severe Gastroparesis
A recent investigation has found that some patients using Ozempic and Wegovy have suffered from severe gastroparesis, also known as stomach paralysis.
This is a serious condition that can significantly impact a patient’s quality of life and requires medical intervention.
Insufficient Warning About Potential Side Effects
Allegations in Ozempic lawsuits may include claims surrounding whether consumers were not sufficiently warned about the potential side effects of these medications, including damage to the gallbladder.
A lack of sufficient warning could potentially lead to unexpected health issues for patients using these drugs.
Eligibility to File a Lawsuit
Users of Ozempic, Wegovy, or other semaglutide medications who were later diagnosed with related gallbladder disease, gastroparesis, or cyclic vomiting syndrome, or bile duct issues may be eligible to file a claim.
Dangerous drug lawsuits typically aim to pursue compensation for medical expenses, pain and suffering, and other damages.
Claims of Acute Gallbladder Disease
Ozempic semaglutide injections may cause acute gallbladder disease.
This is a serious condition that can lead to severe pain and other complications, and may require surgical intervention.
Consumers may be eligible to file claims against Ozempic and Wegovy related to Gallbladder Disease and Stomach Paralysis.
-
Is Ozempic Approved for Weight Loss?
Ozempic has not been approved by the FDA for weight loss.
Wegovy, Ozempic’s “sister drug”, has been approved for weight loss in obese patients.
There has been a significant uptick in off-label use of Ozempic for weight loss in people who are not obese or diagnosed with type 2 diabetes.
Wellness clinics, compounding pharmacies, medical spas, and more have been prescribing Ozempic to people who do not meet criteria for prescriptions, putting them at risk for serious side effects.
Unlawful sales practices regarding Ozempic may also be dwindling the supply of the drug.
-
What is the Active Ingredient in Ozempic?
The active ingredient in Ozempic is semaglutide, a GLP-1 receptor agonist used to treat Type 2 diabetes and, more recently, approved as an anti-obesity medication under the name Wegovy.
-
What is a Compounded Drug?
A compounded drug is a medication often designed to meet specific individual needs or meet demand due to supply chain issues.
Compounded drugs are typically made by mixing different ingredients or altering the dosage form of an existing medication.
-
Is Ozempic Recalled?
No, Ozempic is not recalled.
-
What Kind of Doctor Prescribes Ozempic?
Ozempic is typically prescribed by internal medicine specialists, endocrinologists, or healthcare providers specializing in diabetes obesity medicine.
Ozempic has also been reportedly administered at weight loss clinics, wellness clinics, medical spas, and other facilities.
-
What are the Rare Side Effects of Ozempic?
Rare side effects of Ozempic include hair loss, renal failure, pancreatitis, intestinal obstruction, gallbladder disease, chronic vomiting syndrome, and gastroparesis, among others.
-
What is Gastroparesis?
Gastroparesis, commonly known as stomach paralysis, is a condition characterized by delayed emptying of the stomach, leading to digestive issues, nausea, and other symptoms.
-
What is Gallbladder Disease?
Gallbladder disease refers to a range of conditions affecting the gallbladder, including gallstones and inflammation (cholecystitis).
It can cause abdominal pain, nausea, and other digestive issues, and in severe cases, may require surgical removal of the gallbladder.
-
What is Cyclic Vomiting Syndrome?
Cyclic vomiting syndrome is a rare disorder characterized by recurrent, severe episodes of vomiting with no apparent cause.
These episodes can last for hours or even days, and they are usually followed by symptom-free periods.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
You can learn more about the Ozempic Lawsuit by visiting any of our pages listed below:
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
